Beam Therapeutics INC Form 4 insider transactions

Amy Simon, Chief Medical Officer of Beam Therapeutics Inc., sold 16,667 shares of common stock on July 27, 2026 for $25.74 per share.

Beam Therapeutics Chief Medical Officer Amy Simon sold 373 shares of common stock on June 30, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Beam Therapeutics CEO John M. Evans reports transactions involving the exercise of stock options and sale of common stock, executed under a pre-arranged trading plan.

FMR LLC, a significant holder, disclosed transactions involving Beam Therapeutics Inc. (BEAM) common stock on June 25th and 26th, 2026.

Director Christi Shaw was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Director Kathleen E. Walsh was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Director John Maraganore was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard compensation.

Director Mark Fishman was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Director Chirfi Guindo was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Director Graham K. Cooper was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Beam Therapeutics CEO John M. Evans reports a sale of common stock to cover tax obligations upon vesting of restricted stock units, executed under a Rule 10b5-1 trading plan.

Beam Therapeutics Chief Medical Officer Amy Simon reported a transaction involving the sale of 6,700 shares of common stock on April 1, 2026, to cover tax withholding obligations.

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc., executed a Rule 10b5-1 plan sale of 3,242 shares to cover tax obligations upon vesting of restricted stock units.

Beam Therapeutics Chief Legal Officer Christine Bellon sold 5,956 shares of common stock on April 1, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Giuseppe Ciaramella, President at Beam Therapeutics, sold 11,810 shares of common stock on April 1, 2026, to cover tax withholding obligations related to vested restricted stock units.

Christine Bellon, Chief Legal Officer at Beam Therapeutics, acquired 20,000 shares of common stock through a grant of restricted stock units.

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc., reported a transaction involving 20,000 restricted stock units.

Amy Simon, Chief Medical Officer at Beam Therapeutics, reported a transaction involving restricted stock units.

Beam Therapeutics Chief Financial Officer, Emany Sravan Kumar, acquired 31,750 restricted stock units on March 31, 2026, as part of the company's 2019 Equity Incentive Plan.

Giuseppe Ciaramella, President of Beam Therapeutics Inc., was granted 40,000 restricted stock units (RSUs) on March 31, 2026.

Beam Therapeutics CEO John M. Evans executed pre-scheduled stock option exercises and sales, while also receiving a new restricted stock unit grant.

Beam Therapeutics President Giuseppe Ciaramella exercised stock options and sold 35,000 shares of common stock for a profit under a pre-arranged trading plan.

Beam Therapeutics Inc. granted its SVP, Finance and Treasurer, Bethany J. Cavanagh, 40,000 stock options with an exercise price of $27.62 per share.

Beam Therapeutics Inc. President Giuseppe Ciaramella was granted 80,000 stock options with an exercise price of $27.62, vesting over 48 months.

Beam Therapeutics Inc.'s Chief Financial Officer, Sravan Kumar Emany, was granted 63,500 stock options with an exercise price of $27.62.

Beam Therapeutics' Chief Legal Officer, Christine Bellon, was granted 40,000 stock options with an exercise price of $27.62, vesting over 48 months.

Beam Therapeutics CEO John M. Evans exercised stock options and sold a portion of the resulting shares, while also receiving a new grant of 180,000 stock options.

Beam Therapeutics' Chief Medical Officer, Amy Simon, was granted 88,500 stock options with an exercise price of $27.62, vesting over four years.

Bethany J Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 6,198 shares of common stock for approximately $35.00 per share under a pre-arranged trading plan.

Beam Therapeutics' Chief Legal Officer, Christine Bellon, sold 1,371 shares of common stock for $34 per share under a pre-arranged trading plan.